{'52WeekChange': -0.7102941,
 'SandP52WeekChange': 0.0644362,
 'address1': '215 First Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 49.25,
 'askSize': 1100,
 'averageDailyVolume10Day': 551425,
 'averageVolume': 876690,
 'averageVolume10days': 551425,
 'beta': 2.679551,
 'beta3Year': None,
 'bid': 47,
 'bidSize': 900,
 'bookValue': 16.357,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 47.62,
 'dayLow': 45.35,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.423,
 'enterpriseToRevenue': 186.113,
 'enterpriseValue': 1617138432,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617 299 8379',
 'fiftyDayAverage': 41.64343,
 'fiftyTwoWeekHigh': 174.73,
 'fiftyTwoWeekLow': 25.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 50945398,
 'forwardEps': -9.19,
 'forwardPE': -5.1447225,
 'fromCurrency': None,
 'fullTimeEmployees': 675,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.01831,
 'heldPercentInstitutions': 1.0971,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/sagerx.com',
 'longBusinessSummary': 'Sage Therapeutics, Inc., a biopharmaceutical company, '
                        'develops and commercializes novel medicines to treat '
                        'central nervous system (CNS) disorders. Its lead '
                        'product candidate is ZULRESSO, a proprietary '
                        'intravenous formulation of brexanolone for the '
                        'treatment of postpartum depression (PPD). The '
                        "company's product pipeline also includes SAGE-217, a "
                        'novel neuroactive steroid, which is in Phase III '
                        'clinical trials for treating PPD, major depressive '
                        'disorders, bipolar depression, and generalized '
                        'anxiety disorders; and SAGE-324, a novel compound '
                        'that is in Phase II clinical trial to treat essential '
                        'tremors, as well as has completed Phase I clinical '
                        "trial for epileptiform disorders and Parkinson's "
                        'diseases. In addition, its product pipeline comprises '
                        'SAGE-718, an oxysterol-based positive allosteric '
                        'modulator of the NMDA receptor, which has completed '
                        'Phase I clinical trial for the treatment of '
                        "depression, Huntington's disease, Alzheimer's "
                        'disease, attention deficit hyperactivity disorder, '
                        'schizophrenia, and neuropathic pain. Further, the '
                        'company is developing SAGE-904, an oral therapy that '
                        'is in Phase I clinical trial for disorders associated '
                        'with NMDA hypofunction; and SAGE-689 for '
                        'intramuscular administration. Sage Therapeutics, Inc. '
                        'has a strategic collaboration with Shionogi & Co., '
                        'Ltd. for the development and commercialization of '
                        'SAGE-217 in Japan, Taiwan, and South Korea. The '
                        'company was formerly known as Sterogen Biopharma, '
                        'Inc. and changed its name to Sage Therapeutics, Inc. '
                        'in September 2011. Sage Therapeutics, Inc. was '
                        'founded in 2010 and is headquartered in Cambridge, '
                        'Massachusetts.',
 'longName': 'Sage Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 2454673408,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_141821364',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -643571968,
 'nextFiscalYearEnd': 1640908800,
 'open': 46.4,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.36,
 'phone': '617 299 8380',
 'previousClose': 46.92,
 'priceHint': 2,
 'priceToBook': 2.8905056,
 'priceToSalesTrailing12Months': 282.50357,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 47.62,
 'regularMarketDayLow': 45.35,
 'regularMarketOpen': 46.4,
 'regularMarketPreviousClose': 46.92,
 'regularMarketPrice': 46.4,
 'regularMarketVolume': 478238,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 51917800,
 'sharesPercentSharesOut': 0.1377,
 'sharesShort': 7148625,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6543608,
 'shortName': 'Sage Therapeutics, Inc.',
 'shortPercentOfFloat': 0.1903,
 'shortRatio': 7.63,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'SAGE',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -12.451,
 'twoHundredDayAverage': 46.08662,
 'volume': 478238,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.sagerx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02142'}